Cargando…

Trends in carbapenem resistance in Pre-COVID and COVID times in a tertiary care hospital in North India

BACKGROUND: Carbapenem resistance is endemic in the Indian sub-continent. In this study, carbapenem resistance rates and the prevalence of different carbapenemases were determined in Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa during two periods; Pre-COVI...

Descripción completa

Detalles Bibliográficos
Autores principales: Chatterjee, Nirupama, Nirwan, Pushpa K., Srivastava, Shruti, Rati, Ruchi, Sharma, Lalit, Sharma, Priyanka, Dwivedi, Priyambada, Jaggi, Namita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808733/
https://www.ncbi.nlm.nih.gov/pubmed/36597098
http://dx.doi.org/10.1186/s12941-022-00549-9
_version_ 1784862994676580352
author Chatterjee, Nirupama
Nirwan, Pushpa K.
Srivastava, Shruti
Rati, Ruchi
Sharma, Lalit
Sharma, Priyanka
Dwivedi, Priyambada
Jaggi, Namita
author_facet Chatterjee, Nirupama
Nirwan, Pushpa K.
Srivastava, Shruti
Rati, Ruchi
Sharma, Lalit
Sharma, Priyanka
Dwivedi, Priyambada
Jaggi, Namita
author_sort Chatterjee, Nirupama
collection PubMed
description BACKGROUND: Carbapenem resistance is endemic in the Indian sub-continent. In this study, carbapenem resistance rates and the prevalence of different carbapenemases were determined in Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa during two periods; Pre-COVID (August to October 2019) and COVID (January to February 2021) in a north-Indian tertiary care hospital. METHODS: Details of patient demographics and clinical condition was collated from the Hospital Information System and detection of carbapenemases NDM, OXA-48, VIM, IMP and KPC was done by Polymerase chain reaction (PCR) in 152 and 138 non-consecutive carbapenem resistant isolates during the two study periods respectively. Conjugation assay and sequencing of NDM and OXA-48 gene was done on a few selected isolates. RESULTS: As compared to Pre-COVID period, co-morbidities and the mortality rates were higher in patients harbouring carbapenem resistant organisms during the COVID period. The overall carbapenem resistance rate for all the four organisms increased from 23 to 41% between the two periods of study; with Pseudomonas aeruginosa and Klebsiella pneumoniae showing significant increase (p < 0.05). OXA-48, NDM and co-expression of NDM and OXA-48 were the most common genotypes detected. NDM-5 and OXA-232 were most common variants of NDM and OXA-48 family respectively during both the study periods. CONCLUSION: Higher rate of carbapenem resistance in COVID times could be attributed to increase in number of patients with co-morbidities. However, genetic elements of carbapenem resistance largely remained the same in the two time periods. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12941-022-00549-9.
format Online
Article
Text
id pubmed-9808733
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98087332023-01-04 Trends in carbapenem resistance in Pre-COVID and COVID times in a tertiary care hospital in North India Chatterjee, Nirupama Nirwan, Pushpa K. Srivastava, Shruti Rati, Ruchi Sharma, Lalit Sharma, Priyanka Dwivedi, Priyambada Jaggi, Namita Ann Clin Microbiol Antimicrob Research BACKGROUND: Carbapenem resistance is endemic in the Indian sub-continent. In this study, carbapenem resistance rates and the prevalence of different carbapenemases were determined in Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa during two periods; Pre-COVID (August to October 2019) and COVID (January to February 2021) in a north-Indian tertiary care hospital. METHODS: Details of patient demographics and clinical condition was collated from the Hospital Information System and detection of carbapenemases NDM, OXA-48, VIM, IMP and KPC was done by Polymerase chain reaction (PCR) in 152 and 138 non-consecutive carbapenem resistant isolates during the two study periods respectively. Conjugation assay and sequencing of NDM and OXA-48 gene was done on a few selected isolates. RESULTS: As compared to Pre-COVID period, co-morbidities and the mortality rates were higher in patients harbouring carbapenem resistant organisms during the COVID period. The overall carbapenem resistance rate for all the four organisms increased from 23 to 41% between the two periods of study; with Pseudomonas aeruginosa and Klebsiella pneumoniae showing significant increase (p < 0.05). OXA-48, NDM and co-expression of NDM and OXA-48 were the most common genotypes detected. NDM-5 and OXA-232 were most common variants of NDM and OXA-48 family respectively during both the study periods. CONCLUSION: Higher rate of carbapenem resistance in COVID times could be attributed to increase in number of patients with co-morbidities. However, genetic elements of carbapenem resistance largely remained the same in the two time periods. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12941-022-00549-9. BioMed Central 2023-01-03 /pmc/articles/PMC9808733/ /pubmed/36597098 http://dx.doi.org/10.1186/s12941-022-00549-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chatterjee, Nirupama
Nirwan, Pushpa K.
Srivastava, Shruti
Rati, Ruchi
Sharma, Lalit
Sharma, Priyanka
Dwivedi, Priyambada
Jaggi, Namita
Trends in carbapenem resistance in Pre-COVID and COVID times in a tertiary care hospital in North India
title Trends in carbapenem resistance in Pre-COVID and COVID times in a tertiary care hospital in North India
title_full Trends in carbapenem resistance in Pre-COVID and COVID times in a tertiary care hospital in North India
title_fullStr Trends in carbapenem resistance in Pre-COVID and COVID times in a tertiary care hospital in North India
title_full_unstemmed Trends in carbapenem resistance in Pre-COVID and COVID times in a tertiary care hospital in North India
title_short Trends in carbapenem resistance in Pre-COVID and COVID times in a tertiary care hospital in North India
title_sort trends in carbapenem resistance in pre-covid and covid times in a tertiary care hospital in north india
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808733/
https://www.ncbi.nlm.nih.gov/pubmed/36597098
http://dx.doi.org/10.1186/s12941-022-00549-9
work_keys_str_mv AT chatterjeenirupama trendsincarbapenemresistanceinprecovidandcovidtimesinatertiarycarehospitalinnorthindia
AT nirwanpushpak trendsincarbapenemresistanceinprecovidandcovidtimesinatertiarycarehospitalinnorthindia
AT srivastavashruti trendsincarbapenemresistanceinprecovidandcovidtimesinatertiarycarehospitalinnorthindia
AT ratiruchi trendsincarbapenemresistanceinprecovidandcovidtimesinatertiarycarehospitalinnorthindia
AT sharmalalit trendsincarbapenemresistanceinprecovidandcovidtimesinatertiarycarehospitalinnorthindia
AT sharmapriyanka trendsincarbapenemresistanceinprecovidandcovidtimesinatertiarycarehospitalinnorthindia
AT dwivedipriyambada trendsincarbapenemresistanceinprecovidandcovidtimesinatertiarycarehospitalinnorthindia
AT jagginamita trendsincarbapenemresistanceinprecovidandcovidtimesinatertiarycarehospitalinnorthindia